Novocure announced that Spain's Ministry of Health has made Tumor Treating Fields (TTFields) therapy available through the Spanish National Health System (SNS) for the treatment of adult patients with newly diagnosed glioblastoma. Patients with newly diagnosed gliob lastoma who meet eligibility requirements defined by Spain's Ministry of Health will be able to access TTFields therapy through hospitals and health centers qualified to offer the treatment. TTFields are electric fields that disrupt cancer cell division and are administered through a wearable medical device.
TTFields therapy received a CE Mark for the treatment of newly diagnosed and recurrent WHO Grade 4 Glioblastoma in adults and is commercially available as a treatment for glioblastoma in multiple countries in North America, Europe and Asia. TTFields therapy is reimbursed in Austria, France, Germany, Israel, Japan, Sweden, Switzerland and the United States. Globally, more than 35,000 patients have been treated with TTFields.
These multiple, distinct mechanisms work together to target and kill cancer cells. Due to these multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors.
